THOUGHT-TO-SPEECH SYSTEM LIABILITY: LEGAL FRAMEWORK, NEUROTECHNOLOGY GOVERNANCE AND JUDICIAL PRECEDENTS IN JAPAN

1. INTRODUCTION

Thought-to-Speech System Liability concerns the legal responsibility arising from the development, manufacture, operation and use of technologies that translate neural activity associated with attempted or imagined speech into audible or computer-generated language.

These systems are particularly relevant to brain-computer interfaces (BCIs), assistive communication technologies, neuroprosthetics and medical devices designed for individuals who cannot communicate through conventional speech.

Although these technologies offer significant medical and social benefits, they create complex legal questions concerning inaccurate speech generation, patient consent, mental privacy, data protection, medical negligence, product defects and responsibility for statements generated by artificial intelligence.

A fundamental distinction must be made between a person's actual intended communication and words incorrectly generated by a technological system. An automatically generated statement should not automatically be treated as the user's voluntary declaration.

Japan does not have a separate statute entitled the Thought-to-Speech System Liability Act. Liability is determined through existing medical-device, product-liability, civil-law, privacy and cybersecurity legislation.

2. JAPANESE LEGAL AND REGULATORY FRAMEWORK

A. Pharmaceuticals and Medical Devices Act, 1960 (PMD Act)

The PMD Act regulates medical devices and qualifying medical software intended for diagnosis, treatment or prevention of diseases.

Thought-to-speech systems intended to restore or support communication for patients may qualify as regulated medical devices depending on their intended purpose and risk classification.

Relevant regulatory responsibilities include:

Demonstrating safety and effectiveness.

Obtaining applicable marketing approval, certification or notification.

Maintaining manufacturing and quality-management standards.

Conducting post-marketing safety monitoring.

Reporting qualifying adverse events.

Implementing corrective measures when safety problems arise.

The PMDA evaluates regulated medical devices, while the MHLW exercises relevant regulatory and administrative authority.

B. Product Liability Act, 1994

The Product Liability Act establishes manufacturer liability for damage caused by defective products.

A thought-to-speech device may raise product-defect questions where its hardware, software or integrated components fail to provide the safety reasonably expected under the applicable legal standard.

Potential defects include:

Unreliable speech output.

Inadequate warnings concerning communication errors.

Defective neural-signal interpretation.

Software failures affecting communication.

Insufficient cybersecurity safeguards.

C. Civil Code, 1896

Article 709 establishes tort liability for unlawfully causing damage through intentional or negligent conduct.

Article 415 governs damages arising from non-performance of contractual obligations.

These provisions may apply to developers, manufacturers, healthcare institutions and professionals where the necessary legal requirements are established.

D. Act on the Protection of Personal Information, 2003

Thought-to-speech systems may process highly sensitive information concerning brain activity, communication patterns and medical conditions.

Where such information identifies an individual, applicable personal-data protection requirements must be considered.

E. Industrial and Medical Device Cybersecurity Requirements

Japanese medical-device cybersecurity requirements address vulnerabilities, unauthorized access, network security and product lifecycle risk management.

The MHLW's Essential Principles for Medical Devices, particularly Article 12-3, address cybersecurity risks affecting software-based medical devices.

3. TYPES OF LEGAL LIABILITY

A. Manufacturer Liability

Manufacturers may face liability where defective hardware, software or inadequate warnings cause injury or other legally recognised damage.

B. Medical Professional Liability

Healthcare professionals may face negligence claims where they improperly interpret generated speech, fail to verify important communications or disregard known device limitations.

C. Software Developer Liability

Developers may face contractual or tort liability where defective software, inadequate testing or negligent maintenance causes foreseeable harm.

D. Institutional Liability

Hospitals and research institutions may face responsibility for inadequate supervision, improper device deployment, deficient consent procedures or failure to maintain appropriate safety systems.

E. Privacy and Confidentiality Liability

Unauthorised collection, disclosure or misuse of neural information may create legal consequences under applicable privacy and confidentiality requirements.

4. CONSENT AND MENTAL PRIVACY

Thought-to-speech technology creates a particularly important distinction between internal mental activity and intentionally communicated speech.

A patient may generate neural activity associated with imagined words without intending those words to be communicated publicly.

Accordingly, institutions should distinguish:

Internal neural information.

Attempted communication.

Machine-generated speech.

Speech expressly confirmed by the user.

Informed consent should explain the system's limitations, the possibility of inaccurate output, data collection practices and the circumstances in which generated speech may be stored or shared.

Where communication errors could affect medical treatment, financial decisions or legal declarations, additional confirmation procedures may be necessary.

5. RELEVANT CASE LAWS

There is currently no established Japanese Supreme Court judgment specifically concerning liability for thought-to-speech or brain-computer interface systems. The following decisions provide direct or analogous legal principles.

1. Moore v. Regents of the University of California, 51 Cal. 3d 120 (1990) – Direct Analogous Authority

The California Supreme Court considered whether a patient could claim ownership of biological materials removed during medical treatment and subsequently used to develop a commercially valuable cell line.

The Court rejected the conversion claim concerning the removed cells but recognised other potential claims relating to informed consent and fiduciary duties.

Relevance: The decision provides important comparative principles for ownership, consent and commercial use of sensitive biological information obtained from patients.

2. Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972) – Direct Analogous Authority

The United States Court of Appeals examined a physician's duty to disclose material risks associated with medical treatment.

The Court developed an important informed-consent principle requiring disclosure of risks that a reasonable patient would consider significant.

Relevance: Patients using thought-to-speech systems should receive appropriate information concerning communication errors, technological limitations and foreseeable medical risks.

3. Bolam v. Friern Hospital Management Committee, [1957] 1 WLR 582 – Analogous Authority

The English court considered the standard of care expected from medical professionals.

It established the traditional Bolam principle that professional conduct may be assessed against a responsible body of medical opinion, subject to subsequent judicial developments.

Relevance: The case provides comparative guidance for determining whether healthcare professionals acted reasonably when interpreting and relying upon machine-generated speech.

4. Montgomery v. Lanarkshire Health Board, [2015] UKSC 11 – Direct Analogous Authority

The UK Supreme Court held that medical professionals must disclose material risks and reasonable alternative treatments in accordance with the patient's right to make informed decisions.

Relevance: It is relevant to consent procedures involving experimental or technologically advanced communication devices.

5. Winter v. G.P. Putnam's Sons, 938 F.2d 1033 (9th Cir. 1991) – Analogous Authority

The United States Court of Appeals considered liability arising from allegedly inaccurate information published in a book.

The Court distinguished informational content from products for purposes of product-liability law.

Relevance: The decision raises a useful comparative question concerning whether liability for incorrect AI-generated communication should be analysed as a software-product defect, informational error or professional negligence.

6. Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) – Analogous Authority

The United States Supreme Court examined the reliability and admissibility of scientific expert evidence.

It emphasised judicial assessment of scientific methodology and evidentiary reliability.

Relevance: In disputes involving inaccurate neural decoding, expert evidence concerning system performance, validation and causation may be essential.

These are comparative authorities and do not bind Japanese courts. None directly establishes a legal rule specifically governing thought-to-speech systems.

6. JAPANESE REGULATORY DEVELOPMENTS AND NEUROTECHNOLOGY

Japan has taken steps toward establishing evaluation standards for advanced brain-computer interface devices.

In March 2026, the MHLW issued BCI-specific evaluation indices addressing non-clinical evaluation, usability, clinical evaluation, decoding performance and safety.

The PMDA's 2026 publication identifies BCIs as next-generation medical devices and discusses their potential to restore communication and other functions.

These developments are important because thought-to-speech technologies may require specialised assessment beyond conventional medical-device testing.

The regulatory framework must consider both the accuracy of generated communication and the consequences of incorrect outputs.

7. PRACTICAL COMPLIANCE REQUIREMENTS

Manufacturers, healthcare institutions and technology developers should:

Determine whether the system qualifies as a regulated medical device.

Obtain applicable regulatory approval or certification.

Validate speech-generation performance.

Establish procedures for correcting inaccurate outputs.

Obtain informed consent from users.

Protect neural and medical information.

Maintain cybersecurity throughout the device lifecycle.

Establish clear responsibilities between developers and healthcare professionals.

Maintain incident-reporting and post-market monitoring systems.

Preserve records of software changes, malfunctions and safety investigations.

8. CONCLUSION

Thought-to-Speech System Liability is an emerging area of medical technology law involving artificial intelligence, neurotechnology, medical-device regulation, mental privacy and civil responsibility.

Japan currently addresses these issues through the PMD Act, Product Liability Act, Civil Code, personal-information protection legislation and medical-device cybersecurity requirements.

Comparative judicial decisions concerning informed consent, medical negligence, biological information and scientific evidence provide important principles for determining responsibility when thought-to-speech systems produce inaccurate or harmful communications.

Ultimately, legal governance must protect the patient's autonomy and mental privacy while ensuring that manufacturers, developers and healthcare professionals remain accountable for foreseeable technological failures. The central principle is that machine-generated speech must not automatically be attributed to a person's intentions without appropriate safeguards.